Clinical Trial Update: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma [Phase 2]

View source ↗

Summary

This update concerns a Phase 2 study of TK216 in relapsed or refractory Ewing sarcoma. The trial status is listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• TK216

Snippet

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Conditions: Sarcoma, Ewing | Phase 2 | Status: COMPLETED